I have a PhD in Biochemistry from the Faculty of Science and Technology from Lisbon (UNL), Portugal. I did my post-doctoral research in Malaria with Prof. Maria Mota at Instituto de Medicina Molecular and Instituto Gulbenkian de Ciência for 6 years.
Between 2009 and 2014, I have been a Staff Scientist (Programa Ciência 2008) in the T cell differentiation and Tumor targeting Lab at Instituto de Medicina Molecular, headed by Prof. Bruno Silva-Santos, where I continued studying malaria pathogenesis.
A Phase 1 trial assessing the combination of Exelixis‘ Cabometyx (cabozantinib) and Genentech‘s Tecentriq (atezolizumab) in locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC) is set to ... Read more
The PD-L1 molecule can mask cancer’s pain, enabling malignancies to develop and spread without sending alarms to the immune system, according to a study. Researchers from Duke University School ... Read more
Researchers at the Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai revealed a new mechanism by which radiotherapy can successfully eradicate melanoma. These findings were ... Read more
The U.S. Food and Drug Administration (FDA) approved Bristol-Myers Squibb‘s Yervoy (ipilimumab), 10 mg/kg, as an adjuvant therapy in patients with resectable Stage III cutaneous melanoma, making it the only immune checkpoint inhibitor approved by FDA ... Read more
Researchers from Helmholtz Zentrum München, Germany, revealed the mechanisms that inhibit natural killer (NK) cells and how this phenomenon can be overcomed in the context of malignant lymphoma. The study ... Read more
Clinical trials are being conducted by Ludwig Cancer Research (Ludwig) and the Cancer Research Institute (CRI) to evaluate Durvalumab, a checkpoint blockade antibody, alone and in combination with Tremelimumab, ... Read more
Research conducted by ISA Pharmaceuticals B.V. revealed a beneficial effect of Synthetic Long Peptide (SLP®) on intratumoral macrophages in cancer induced by human papilloma virus 16 (HPV16). The study entitled ... Read more
A new study showing that the PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, decreased the growth of tumors in 76% of individuals with pleural mesothelioma, a rare and fatal ... Read more
Pin It on Pinterest